Conatus Pharmaceuticals Inc. (CNAT)

[chainma1l]

Beat consensus by 8 cents.
Not a lot of actual meaning behind that, but sounds good.

4:16 pm Conatus Pharma reports Q2 results (CNAT) :
•Reports Q2 (Jun) loss of $0.30 per share, $0.08 better than the Capital IQ Consensus of ($0.38); revenues were unchanged from the year-ago period at $0 mln.
•Cash, cash equivalents and marketable securities were $30.2 million at June 30, 2016, compared with $36.5 million at December 31, 2015. The company believes current financial resources are sufficient to maintain operations and ongoing clinical trials for at least the next 12 months.